Stabilised Ceretec - Norvégia - norvég - Statens legemiddelverk

stabilised ceretec -

ge healthcare as - kobolt(ii)kloridheksahydrat / eksametazim - preparasjonssett til radioaktive legemidler

Neurolite - Norvégia - norvég - Statens legemiddelverk

neurolite -

lantheus mi uk ltd. - bicisatdihydroklorid ad tc-99m bicisate - pulver og væske til injeksjonsvæske, oppløsning

Tisseel Norvégia - norvég - Statens legemiddelverk

tisseel

baxter medical ab - fibrinogen, humant / aprotinin / trombin, humant / kalsiumklorid - oppløsning til vevslim - / 3000 kiu/ ml / 500 ie/ ml / 40 mikromol/ ml

Gadovist 1 mmol/ ml Norvégia - norvég - Statens legemiddelverk

gadovist 1 mmol/ ml

bayer ab - solna - gadobutrol - injeksjonsvæske, oppløsning - 1 mmol/ ml

Irinokabi 20 mg/ ml Norvégia - norvég - Statens legemiddelverk

irinokabi 20 mg/ ml

fresenius kabi oncology plc - irinotekanhydrokloridtrihydrat - konsentrat til infusjonsvæske, oppløsning - 20 mg/ ml

Dimethyl fumarate Polpharma Európai Unió - norvég - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Feiba 50 E/ ml Norvégia - norvég - Statens legemiddelverk

feiba 50 e/ ml

baxalta innovations gmbh - faktor viii hemmer bypassaktivitet - pulver og væske til infusjonsvæske, oppløsning - 50 e/ ml

Sandimmun 50 mg/ ml Norvégia - norvég - Statens legemiddelverk

sandimmun 50 mg/ ml

novartis norge (2) - ciklosporin - konsentrat til infusjonsvæske, oppløsning - 50 mg/ ml

Yasminelle 28 0.02 mg / 3 mg Norvégia - norvég - Statens legemiddelverk

yasminelle 28 0.02 mg / 3 mg

bayer ab - solna - etinyløstradiolbetadeksklatrat / drospirenon - tablett, filmdrasjert - 0.02 mg / 3 mg

Verzenios Európai Unió - norvég - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - bryst neoplasms - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.